Market Size
The Global Endometrial Cancer Market reached USD 18.7 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 27.3 billion by 2031. The global endometrial cancer market is expected to exhibit a CAGR of 4.9% during the forecast period (2024-2031). The increasing cases of endometrial cancer, increase in the prevalence of risk factors, growing awareness, funding initiatives, increasing search activities favorable reimbursement policies, and market developments such as product launches, product authorizations, alliances, acquisitions, coalitions, and expansion among others are expected to boost the global endometrial cancer market growth in the forecast period. The key market players in this market include Pfizer, AstraZeneca PLC, Ability Pharma (Ability Pharmaceuticals, SL), and GlaxoSmithKline, and Elekta AB among others.
Market Scope
| Metrics | Details |
| CAGR | 4.9% |
| Size Available for Years | 2022-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$) |
| Segments Covered | Type, Therapy Type, End-user |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For More Insights Request Free Sample
Market Dynamics
Increasing Research Activities Drive The Growth Of The Endometrial Cancer Market
The increasing clinical research activities are expected to drive the global endometrial cancer market growth in the forecast period. For instance, in July 2022, Canada-based Sunnybrook Health Sciences Centre supported a clinical investigation to estimate the influence of megestrol acetate on grade 2 endometrioid endometrial cancer in individuals waiting for standard procedure.
Also, in February 2022, Karyopharm Therapeutics Inc., an innovation-driven pharmaceutical corporation established in the United States, registered positive top-line outcomes from the Phase 3 Selinexor endometrial cancer investigation, assessing the effectiveness and safety of front-line maintenance treatment utilizing selinexor in individuals with progressive or recurrent endometrial tumors.
The Increasing Efforts To Spread Awareness Are Expected To Present The Global Endometrial Cancer Market With Growth Opportunities.
The increasing initiatives from different organizations to spread awareness about gynecological cancer are presenting the endometrial cancer market with lucrative growth opportunities. For instance, in May 2023, the International Gynecologic Cancer Society (IGCS) in partnership with over 25 member organizations from al-over the globe, declared June as the inaugural Uterine Cancer Awareness Month.
The observance is a component of a multinational endeavor directed by the IGCS to increase awareness regarding uterine cancer (also called endometrial cancer) and encourage the necessity for additional research budget, society teaches, and unbiased access to high-quality care. The IGCS is supported in this endeavor by advocacy bodies all over the globe, such as the Endometrial Cancer Action Network for African Americans (ECANA), Facing Our Risk of Cancer Empowered (FORCE), SHARE, and the Uterine Cancer Awareness Network (UCAN), among others.
The High Cost of Treatment Is Estimated To Hamper The Global Endometrial Cancer Market During The Forecast Period.
The high cost of gynecological cancer treatment is expected to slow the global endometrial cancer market growth in the forecast period. For instance, according to the NIH, estimations the yearly medical cost associated with gynecologic cancers was about $3.8 billion, with a moderate expense of $6,293 for each patient. The most elevated yearly expenditure per individual was ovarian cancer ($13,566), heeded by uterine cancer ($6,852), and cervical cancer ($2,312).
Market Segment Analysis
The global endometrial cancer market is segmented based on type, therapy type, end-user and region.
The Immunotherapy Segment is Estimated to Dominate the Global Endometrial Cancer Market.
Owing to the increasing developments in immunotherapy for endometrial cancer the immunotherapy segment is expected to dominate the global market holding 34.9% of the global market share. For instance, in March 2023, investigators delivered new interim outcomes from the Phase III RUBY clinical investigations that might demonstrate a new benchmark of care for endometrial cancer treatment.
GSK, a British multinational biotechnology and pharmaceutical corporation’s investigation estimated the programmed death receptor-1 (PD-1)-blocking antibody Jemperli (dostarlimab). Outcomes from the foremost piece of the Phase III clinical investigations were submitted in a virtual plenary session, organized by the European Society for Medical Oncology (ESMO).
Market Geographical Share
North America Estimated to hold Approximately 39.6% of the Market Share by 2030, Owing to The Increasing Prevalence and Initiatives in This Region.
Owing to the high prevalence and developed healthcare system North America is estimated to dominate the global market holding around 39.6% of the total market share by 2030. For instance, in the United States, cancer of the endometrium (the lining of the uterus) is a highly typical cancer of the female reproductive organs. The American Cancer Society estimates that around 66,200 new cases of cancer of the body of the uterus (uterine body or corpus) will be detected and almost 13,030 females will die because of uterine body cancers in 2023.
These estimations enclose both endometrial cancers and uterine sarcomas. Nearly 10% of uterine body cancers are sarcomas, so the exact numerals for endometrial cancer patients and deaths are a little lower compared to these estimates.
Market Key Players
The major global players in the endometrial cancer market include Pfizer, AbilityPharma (Ability Pharmaceuticals, SL), Elekta AB, GlaxoSmithKline, Eisai Co., Ltd., ARIAD Pharmaceuticals, Novartis, AstraZeneca PLC, Karyopharm Therapeutics, and Bayer AG among others.
Russia Ukraine Conflict Analysis
The Russia-Ukraine brawl is considered to carry a moderate mark on the global endometrial cancer market, as the low prevalence and dearth of critical market players in this region. Yet, persisting to countenance raids from Russian troops, Ukrainian infirmaries are pushed by increasing numerals of deaths and specified medical aids. There are deficiencies across all kinds of drugs. Again, the consequence of the import and export of fundamental materials are predicted to have a small influence on the global endometrial cancer market growth in the forecast period.
Key Developments
- In March 2022, the United States Food and Drug Administration (FDA) authorized KEYTRUDA, Merck, an American multinational pharmaceutical corporation’s anti-PD-1 treatment, as a single agent for the therapy of individuals with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as defined by an FDA-approved test.
- In November 2021, Eisai Co., Ltd., a Japanese pharmaceutical corporation, and Merck & Co., Inc., an American multinational pharmaceutical corporation, obtained the European Commission authorization for the combination of LENVIMA, the orally obtainable multiple receptor tyrosine kinase inhibitor discovered, plus KEYTRUDA, the anti-PD-1 therapy in the therapy of progressive or recurrent endometrial carcinoma in adults who have condition advancement on or following previous therapy with a platinum‑containing treatment in any setting and who are not nominees for remedial surgery or radiation.
Why Purchase the Report?
- To visualize the global endometrial cancer market segmentation based on type, therapy type, end-user and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of endometrial cancer market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global endometrial cancer market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
